Compliance, persistence, and switching patterns for ACE inhibitors and ARBs

American Journal of Managed Care

Volumn 17, Issue 9, 2011, Pages 609-616

  Vegter, Stefan ^a   Nguyen, Nhu Ho ^a   Visser, Sipke T ^a   De Jong van Den Berg, Lolkje T W ^a   Postma, Maarten J ^a   Boersma, Cornelis ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; RAMIPRIL; VALSARTAN;

ADULT; AGE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG PERSISTENCE; DRUG SWITCHING BEHAVIOR; DRUG USE; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REFERENCE DATABASE; SEX; TIME; TREATMENT DURATION;

AGE FACTORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DATABASES, FACTUAL; DECISION MAKING; FEMALE; HUMANS; INCIDENCE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; STATISTICS AS TOPIC; TIME FACTORS; UNITED STATES;

EID: 80053020175     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121-2158.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302.
3. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
4. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. (Pubitemid 34286536)
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [published correction appears in N Engl J Med. 2000;342(10):748]. N Engl J Med. 2000;342(3):145-153.
6. Ruggenenti P, Perna A, Loriga G, et al; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939-946. (Pubitemid 41071427)
7. Bohm M, Baumhäkel M, Mahfoud F, Werner C. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. Cardiology. 2010;117(3):163-173.
8. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med. 2004;164(8):910-913. (Pubitemid 38520634)
9. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23(12):1999-2010. (Pubitemid 34073191)
10. Miller AE, Cziracky M, Spinler SA. ACE inhibitors versus ARBs: comparison of practice guidelines and treatment selection considerations. Formulary. 2006;41:274-284. (Pubitemid 44047999)
11. Hernandez AF, Harrington RA. Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? CMAJ. 2008;178(10):1316-1319. (Pubitemid 351678355)
12. Siragy HM. Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther. 2010;27(5):257-284.
13. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials [published correction appears in JAMA. 1995;274(6):462]. JAMA. 1995;273(18):1450-1456.
14. Pilote L, Abrahamowicz M, Eisenberg M, Humphries K, Behlouli H, Tu JV. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ. 2008;178(10):1303-1311. (Pubitemid 351678353)
15. Hansen ML, Gislason GH, Kober L, et al. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol. 2008;65(2):217-223. (Pubitemid 351171258)
16. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207-1225. (Pubitemid 351822111)
17. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. 2002;16(8):569-575. (Pubitemid 35021364)
18. Dusing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep. 2001;3(6):488-492.
19. Ambrosioni E, Leonetti G, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens. 2000;18(11):1691-1699.
20. Chen K, Chiou CF, Plauschinat CA, Frech F, Harper A, Dubois R. Patient satisfaction with antihypertensive therapy. J Hum Hypertens. 2005;19(10):793-799. (Pubitemid 41486142)
21. Schirm E, Monster TB, de Vries R, van den Berg PB, de Jong-van den Berg LT, Tobi H. How to estimate the population that is covered by community pharmacies? an evaluation of two methods using drug utilisation information. Pharmacoepidemiol Drug Saf. 2004;13(3):173-179.
22. Tobi H, van den Berg PB, de Jong-van den Berg LT. The interaction database: synergy of science and practice in pharmacy. In: Brause RW, Hanisch E, eds. Medical Data Analysis. Berlin, Germany: Springer-Verlag; 2000:206-211.
23. Vegter S, de Jong-van den Berg LT. Choice of first antihypertensive- comparison between the Irish and Dutch setting. Br J Clin Pharmacol. 2008;66(2):313-315.
24. Vegter S, de Jong-van den Berg LT. Misdiagnosis and mistreatment of a common side-effect - angiotensin-converting enzyme inhibitorinduced cough. Br J Clin Pharmacol. 2010;69(2):200-203.
25. Leufkens HGM, Urquhart J. Automated pharmacy record linkage in the Netherlands. In: Strom BL, ed. Pharmacoepidemiology. Chichester, UK: John Wiley & Sons Ltd; 2008:347-360.
26. WHO Expert Committee. The selection and use of essential medicines. World Health Organ Tech Rep Ser. 2009;958:1-242.
27. Tu K, Manuel D, Lam K, Kavanagh D, Mitiku TF, Guo H. Diabetics can be identified in an electronic medical record using laboratory tests and prescriptions. J Clin Epidemiol. 2011;64(4):431-435.
28. Gray J, Majeed A, Kerry S, Rowlands G. Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. BMJ. 2000;321(7260):548-550.
29. Udris EM, Au DH, McDonell MB, et al. Comparing methods to identify general internal medicine clinic patients with chronic heart failure. Am Heart J. 2001;142(6):1003-1009. (Pubitemid 33138140)
30. Penning-van Beest F, van Herk-Sukel M, Gale R, Lammers JW, Herings R. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir Med. 2011;105(2):259-365.
31. Segura J, Christiansen H, Campo C, Ruilope LM. How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria? Curr Hypertens Rep. 2003;5(5):426-429. (Pubitemid 38898966)
32. Bergman U. The history of the Drug Utilization Research Group in Europe. Pharmacoepidemiol Drug Saf. 2006;15(2):95-98.
33. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47. (Pubitemid 351160875)
34. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12. (Pubitemid 46161090)
35. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303-2310.
36. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28(9):1411-1424; discussion 1410.
37. Sharma PP. Predictors and Consequences of Nonadherence to Antihypertensive Medication [dissertation]. Rutgers, The State University of New Jersey; 2007.
38. Vink NM, Klungel OH, Stolk RP, Denig P. Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf. 2009;18(2):159-165.
39. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26(4):819-824. (Pubitemid 351354932)
40. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
41. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499-509. (Pubitemid 39469033)
42. Vitry A, Lai YH. Advertising of antihypertensive medicines and prescription sales in Australia. Intern Med J. 2009;39(11):728-732.
43. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160(1):41-46. (Pubitemid 29054225)
44. Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev. 2007;15(5):257-263. (Pubitemid 47282034)
45. Gogovor A, Dragomir A, Savoie M, Perreault S. Comparison of persistence rates with angiotensin-converting enzyme inhibitors used in secondary and primary prevention of cardiovascular disease. Value Health. 2007;10(5):431-441. (Pubitemid 47485661)
46. Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011;65(3):253-263.
47. Enlund H. Measuring patient compliance in antihypertensive therapy-some methodological aspects. J Clin Hosp Pharm. 1982;7(1):43-51.
48. Gumbs PD, Verschuren WM, Mantel-Teeuwisse AK, et al. Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study. Drugs Aging. 2006;23(9):733-741. (Pubitemid 44536907)
49. Vegter S, Kölling P, Töben M, Visser ST, de Jong-van den Berg LT. Replacing hormone therapy -i s the decline in prescribing sustained, and are nonhormonal drugs substituted? Menopause. 2009;16(2):329-335.